These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11221880)

  • 1. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
    Levine DA; Boyd J
    Cancer Res; 2001 Feb; 61(3):908-11. PubMed ID: 11221880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
    Li AJ; McAllister P; Karlan BY
    Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
    Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R
    Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer.
    Santarosa M; Bidoli E; Gallo A; Steffan A; Boiocchi M; Viel A
    Oncol Rep; 2002; 9(3):639-44. PubMed ID: 11956643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of endometrial carcinoma associated with BRCA mutation.
    Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
    Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study.
    Haiman CA; Brown M; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Kantoff PW; Hunter DJ
    Cancer Res; 2002 Feb; 62(4):1045-9. PubMed ID: 11861380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
    Suter NM; Malone KE; Daling JR; Doody DR; Ostrander EA
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):127-35. PubMed ID: 12582022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility.
    Wu MH; Chou YC; Yu CP; Yang T; You SL; Chen CJ; Sun CA
    Eur J Cancer Prev; 2008 Aug; 17(4):317-22. PubMed ID: 18562955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome.
    Ludwig AH; Murawska M; Panek G; Timorek A; Kupryjanczyk J
    Endocr Relat Cancer; 2009 Sep; 16(3):1005-16. PubMed ID: 19458022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
    Kim SC; Ju W; Mahavni V; Geisler JP; Buller RE
    Int J Gynecol Cancer; 2006; 16 Suppl 1():190-4. PubMed ID: 16515589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
    Li AJ; Elmore RG; Pavelka JC; Karlan BY
    Gynecol Oncol; 2007 Dec; 107(3):420-3. PubMed ID: 17825390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
    Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
    Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
    Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
    Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.